Andere Sprachen Nektar Therapeutics

Aktien

165417

US6402681083

NKTR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:02 01.05.2024			% 5 Tage	% 1. Jan.
1,65 ^USD	+13,01 %		+16,20 %	+192,04 %

24.04.	Biolojic Design gibt bekannt, dass Nektar Therapeutics seine Lizenzoption zur Entwicklung eines KI-entwickelten agonistischen Antikörpers, der auf TNFR2 abzielt, für die Behandlung von Autoimmunkrankheiten ausgeübt hat	CI
05.03.	Nektar Therapeutics beginnt Phase 2b-Studie für Rezpegaldesleukin bei Patienten mit schwerer Alopecia Areata	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nektar Therapeutics : SCHEDULE 14A	26.04.
Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	24.04.
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference	25.03.
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	22.03.
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	19.03.
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	05.03.
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05.03.
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05.03.
Nektar: Q4 Earnings Snapshot	04.03.
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	04.03.
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	04.03.
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04.03.
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX	04.03.
North American Morning Briefing : Stock Futures -2-	04.03.
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC	04.03.
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference	28.02.
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets	27.02.
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	22.01.
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA	04.01.
Nektar Therapeutics(NasdaqCM:NKTR) dropped from NASDAQ Biotechnology Index	15.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nektar Therapeutics

Aktien

165417

US6402681083

NKTR

Andere Sprachen

Filter